Migräne (Topiramate)

Topiramate, the active ingredient in Migräne, is an anticonvulsant presented as an oral tablet for oral use. It is employed in the prophylaxis of migraine attacks and as adjunctive therapy for various seizure disorders in adults and children.

GNH USA supplies Migräne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. All batches are manufactured under EU GMP guidelines and are fully traceable.

Topiramate is used in neurological conditions that involve abnormal neuronal excitability.

Migraine prophylaxis: reduces the frequency and severity of migraine attacks in adults. Partial‑onset seizures (epilepsy): used as adjunctive therapy to control seizure episodes. Generalized tonic‑clonic seizures: added to existing regimens to improve seizure control.

Topiramate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Paresthesia: tingling or numbness in the limbs. - Altered taste: reduced ability to perceive sweet flavors. - Weight loss: mild to moderate decrease in body weight. - Fatigue: feeling of tiredness or low energy.

Serious or Rare Side Effects: - Metabolic acidosis: accumulation of acid in the blood. - Kidney stones: formation of renal calculi due to altered urine pH. - Acute angle‑closure glaucoma: sudden increase in intra‑ocular pressure.

Before initiating therapy with Topiramate, several precautionary measures should be considered.

Renal function: assess baseline kidney function and monitor periodically. Pregnancy: avoid use during pregnancy as it is classified as category D. History of glaucoma: evaluate intra‑ocular pressure and monitor for visual changes. Cognitive effects: watch for confusion, difficulty concentrating or memory problems. Concomitant carbonic anhydrase inhibitors: avoid due to increased risk of metabolic acidosis. Store at room temperature below 25°C: keep in the original container, protect from moisture.

Topiramate can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may increase risk of hyperammonemia and hepatic toxicity. - Carbonic anhydrase inhibitors (e.g., acetazolamide): additive risk of metabolic acidosis. - CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce topiramate plasma concentrations.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy, requiring alternative contraception. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedative effects. - Lithium: combined use may increase the likelihood of kidney stone formation.